The Henderson Research Centre was established in 1988 as a joint initiative of McMaster University and Hamilton Health Sciences. The three core research programs at HRC include:
Experimental Thrombosis and Atherosclerosis (ETA) Program, led by Dr Jeff Weitz (right), which conducts fundamental research on the interplay between thrombosis, atherosclerosis, diabetes, cancer, and inflammation.
Clinical Thromboembolism Program (CTP), which performs research that informs optimal prevention, diagnosis and treatment of patients with thrombotic problems, as well as research in knowledge translation aimed at optimal transfer of this information to the bedside. This program,which is regional in nature and includes all HHS sites as well as St. Joseph’s Healthcare, also provides clinical care to patients in the hospital and in the community who have, or are at risk, for thrombotic disorders.
Clinical Trials Methodology Group (CTMG), which designs, conducts and analyzes the results of clinical trials. CTMG not only works closely with the Clinical Thromboembolism Program, but also (a) is involved with the translational research activities of the Experimental Thrombosis and Atherosclerosis Group, (b) houses the Ontario Clinical Oncology Group, and (c) designs, conducts and analyzes the results of clinical trials for prevention, diagnosis and treatment of cancer.
After more than two decades of success, the Henderson Research Centre has relocated to the David Braley Cardiac, Vascular and Stroke Research Institute the Hamilton General campus which not only provides space for further expansion, but also creates synergies with the Population Health Research Institute. It remains focused on its mission of research excellence in thrombosis and atherosclerosis and includes the Experimental Thrombosis and Atherosclerosis Program, and the Clinical Thromboembolism Program, the Biometrics Group and the Comparative Medicine Program, which focuses on the translation of basic research findings into clinically relevant models prior to evaluation in humans.
In celebration of its new location, the institute was renamed the Thrombosis & Atherosclerosis Research Institute (TaARI) effective January 2010.
The Clinical Thromboembolism Group at McMaster University has been a leading centre in thrombosis research for over three decades and has trained scores of scientists who now head up thrombosis units throughout the world.
Dr. Jack Hirsh (right) founded the group and led the development of diagnostic techniques that have improved and simplified the diagnosis of thromboembolism disorders. His investigation of heparin and warfarin set the standards for their dosing and clinical use internationally. He also pioneered the standardization of laboratory monitoring and dosing of warfarin (which led to the development of the INR), thereby increasing its safety and expanding its use to patients that had been denied the benefit of this oral anticoagulant, and contributed to the discovery of unique characteristics of low-molecular-weight heparins.
Whereas several of the easy “questions” in venous thromboembolism (VTE) have been answered including the initial therapy and intensity of treatment, many dilemmas remain to be solved but will require much larger or global studies.
Click here for more information on the Clinical Thromboembolism Group.